Key Takeaways
- • Cosette Pharmaceuticals, Inc. reports full availability of RYANODEX (dantrolene sodium) for injectable suspension in the United States and international markets, following its June 2026 acquisition of the product from Eagle Pharmaceuticals.
- • Cosette states it completed a successful supply chain transition after the acquisition and is using its established manufacturing and distribution capabilities to maintain supply for healthcare providers.
- • Company leadership frames the deal as part of a commitment to expanding access to important medicines, with a stated priority on dependable hospital and provider access to the product.
- • Cosette is a Bridgewater, New Jersey-based specialty pharmaceutical company with 350+ employees, backed by Avista Healthcare Partners and funds managed by Hamilton Lane.
Summary
Cosette Pharmaceuticals, Inc. announced via Business Wire that RYANODEX (dantrolene sodium) for injectable suspension is fully stocked and available in the United States and international markets. The announcement follows Cosette's June 2026 acquisition of the RYANODEX product from Eagle Pharmaceuticals and what the company describes as a successful supply chain transition. Cosette says it is leveraging its established manufacturing and distribution capabilities to maintain a dependable supply of the treatment for healthcare providers.
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, said the acquisition reflects the company's commitment to expanding access to important medicines and ensuring the supporting infrastructure is in place. He cited the company's ability to integrate RYANODEX and secure a dependable supply as evidence of organizational strength. Brad Leonard, Vice President, Commercial Operations at Cosette, said the company's priority is ensuring hospitals and healthcare providers have dependable access to the product so they can focus on delivering timely patient care.
According to the company's boilerplate, Cosette is a U.S.-based specialty pharmaceutical company headquartered in Bridgewater, New Jersey, with more than 350 team members. The company is backed by Avista Healthcare Partners, a healthcare-focused private equity firm, and by funds managed by Hamilton Lane (Nasdaq: HLNE). The release does not disclose the acquisition price or detailed supply volumes. Full prescribing information is available from the company.
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, said the acquisition reflects the company's commitment to expanding access to important medicines and ensuring the supporting infrastructure is in place. He cited the company's ability to integrate RYANODEX and secure a dependable supply as evidence of organizational strength. Brad Leonard, Vice President, Commercial Operations at Cosette, said the company's priority is ensuring hospitals and healthcare providers have dependable access to the product so they can focus on delivering timely patient care.
According to the company's boilerplate, Cosette is a U.S.-based specialty pharmaceutical company headquartered in Bridgewater, New Jersey, with more than 350 team members. The company is backed by Avista Healthcare Partners, a healthcare-focused private equity firm, and by funds managed by Hamilton Lane (Nasdaq: HLNE). The release does not disclose the acquisition price or detailed supply volumes. Full prescribing information is available from the company.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.